Skip to main content
Top
Published in: BMC Public Health 1/2012

Open Access 01-12-2012 | Research article

Effect of scheduled monitoring of liver function during anti-Tuberculosis treatment in a retrospective cohort in China

Authors: Shanshan Wu, Yinyin Xia, Xiaozhen Lv, Yuan Zhang, Shaowen Tang, Zhirong Yang, Dehua Tu, Peiyuan Deng, Shiming Cheng, Xiaomeng Wang, Yanli Yuan, Feiying Liu, Daiyu Hu, Siyan Zhan

Published in: BMC Public Health | Issue 1/2012

Login to get access

Abstract

Background

Data on effect of regular liver function monitoring during anti-TB treatment is limited in China. This study aimed to evaluate the effects of scheduled liver function monitoring on identification of asymptomatic liver damage and anti-TB treatment outcomes during anti-TB treatment.

Methods

A retrospective analysis was performed based on a national-level cohort study. A total of 273 patients developing liver dysfunction were divided into two groups, 111 patients who were diagnosed through scheduled liver function test within two months after initiation of anti-TB treatment formed scheduled monitoring group, others who were diagnosed due to developing symptoms formed passive detection group (n = 162). The two groups were compared through clinical features, prognosis of liver dysfunction and impact on anti-TB treatment using propensity score weighting analysis.

Results

33.3% of 273 patients did not have any clinical symptoms, including 8 with severe hepatotoxicity. 1.8% in scheduled monitoring group and 11.1% in passive detection group required hospitalization (P = 0.004). Regarding the prognosis of liver dysfunction, most patients recovered, no death happened in scheduled monitoring group while 3 died in passive detection group. In terms of impact on anti-TB treatment, 35.1% in scheduled monitoring group and 56.8% in passive detection group changed their anti-TB treatment (P = 0.001).

Conclusions

Scheduled monitoring is effective in identifying asymptomatic liver damage, reducing hospitalization rate and improving compliance of anti-TB treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference WHO: Global tuberculosis control: WHO Report 2011. 2011, WHO document WHO/CDS/TB WHO: Global tuberculosis control: WHO Report 2011. 2011, WHO document WHO/CDS/TB
2.
go back to reference WHO: An expanded DOTS framework for effective tuberculosis control. Stop TB Communicable Diseases. 2002, WHO document WHO/CDS/TB, 1-20. WHO: An expanded DOTS framework for effective tuberculosis control. Stop TB Communicable Diseases. 2002, WHO document WHO/CDS/TB, 1-20.
3.
go back to reference Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D: Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003, 167: 1472-1477. 10.1164/rccm.200206-626OC.CrossRefPubMed Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D: Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003, 167: 1472-1477. 10.1164/rccm.200206-626OC.CrossRefPubMed
4.
go back to reference Kaona FA, Tuba M, Siziya S, Sikaona L: An assessment of factors contributing to treatment adherence and knowledge of TB transmission among patients on TB treatment. BMC Public Health. 2004, 4: 68-10.1186/1471-2458-4-68.CrossRefPubMedPubMedCentral Kaona FA, Tuba M, Siziya S, Sikaona L: An assessment of factors contributing to treatment adherence and knowledge of TB transmission among patients on TB treatment. BMC Public Health. 2004, 4: 68-10.1186/1471-2458-4-68.CrossRefPubMedPubMedCentral
5.
go back to reference Wares DF, Singh S, Acharya AK, Dangi R: Non-adherence to tuberculosis treatment in the eastern Tarai of Nepal. Int J Tuberc Lung Dis. 2003, 7: 327-335.PubMed Wares DF, Singh S, Acharya AK, Dangi R: Non-adherence to tuberculosis treatment in the eastern Tarai of Nepal. Int J Tuberc Lung Dis. 2003, 7: 327-335.PubMed
6.
go back to reference WHO: Anti-tuberculosis drug resistance in the world report no. 4. 2008, WHO/HTM/TB/2008.394 WHO: Anti-tuberculosis drug resistance in the world report no. 4. 2008, WHO/HTM/TB/2008.394
7.
go back to reference Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C: Tuberculosis. Lancet. 2003, 362: 887-899. 10.1016/S0140-6736(03)14333-4.CrossRefPubMed Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C: Tuberculosis. Lancet. 2003, 362: 887-899. 10.1016/S0140-6736(03)14333-4.CrossRefPubMed
8.
go back to reference WHO: Treatment of tuberculosis: guidelines for national programs. 1997, WHO/TB/97220 WHO: Treatment of tuberculosis: guidelines for national programs. 1997, WHO/TB/97220
9.
go back to reference Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloguin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR: ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee: An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006, 174: 935-952. 10.1164/rccm.200510-1666ST.CrossRefPubMed Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloguin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR: ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee: An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006, 174: 935-952. 10.1164/rccm.200510-1666ST.CrossRefPubMed
10.
go back to reference Joint Tuberculosis Committee of the British Thoracic Society: Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax. 1998, 53: 536-548.CrossRef Joint Tuberculosis Committee of the British Thoracic Society: Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax. 1998, 53: 536-548.CrossRef
11.
go back to reference Migliori GB, Raviglione MC, Schaberg T, Davies PDO, Zellweger JP, Grzemska M, Mihaescu T, Clancy L, Casali L: Tuberculosis management in Europe. Task Force of the European Respiratory Society (ERS), the World Health Organization (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region. Eur Respir J. 1999, 14: 978-992.CrossRefPubMed Migliori GB, Raviglione MC, Schaberg T, Davies PDO, Zellweger JP, Grzemska M, Mihaescu T, Clancy L, Casali L: Tuberculosis management in Europe. Task Force of the European Respiratory Society (ERS), the World Health Organization (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region. Eur Respir J. 1999, 14: 978-992.CrossRefPubMed
12.
go back to reference Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R: Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008, 23: 192-202. 10.1111/j.1440-1746.2007.05207.x.CrossRefPubMed Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R: Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008, 23: 192-202. 10.1111/j.1440-1746.2007.05207.x.CrossRefPubMed
13.
go back to reference Xia YY, Hu DY, Liu FY, Wang XM, Yuan YL, Tu DH, Chen YX, Zhou L, Zhu LZ, Gao WW, Wang HY, Chen DF, Yang L, He PP, Li XT, He YJ, Sun F, Zhan SY: Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS). BMC Public Health. 2010, 10: 267-10.1186/1471-2458-10-267.CrossRefPubMedPubMedCentral Xia YY, Hu DY, Liu FY, Wang XM, Yuan YL, Tu DH, Chen YX, Zhou L, Zhu LZ, Gao WW, Wang HY, Chen DF, Yang L, He PP, Li XT, He YJ, Sun F, Zhan SY: Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS). BMC Public Health. 2010, 10: 267-10.1186/1471-2458-10-267.CrossRefPubMedPubMedCentral
14.
go back to reference Shang P, Xia Y, Liu F, Wang X, Yuan Y, Hu D, Tu D, Chen Y, Deng P, Cheng S, Zhou L, Ma Y, Zhu L, Gao W, Wang H, Chen D, Yang L, He P, Wu S, Tang S, Lv X, Shu Z, Zhang Y, Yang Z, Chen Y, Li N, Sun F, Li X, He Y, Garner P, et al: Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS One. 2011, 6: e21836-10.1371/journal.pone.0021836.CrossRefPubMedPubMedCentral Shang P, Xia Y, Liu F, Wang X, Yuan Y, Hu D, Tu D, Chen Y, Deng P, Cheng S, Zhou L, Ma Y, Zhu L, Gao W, Wang H, Chen D, Yang L, He P, Wu S, Tang S, Lv X, Shu Z, Zhang Y, Yang Z, Chen Y, Li N, Sun F, Li X, He Y, Garner P, et al: Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS One. 2011, 6: e21836-10.1371/journal.pone.0021836.CrossRefPubMedPubMedCentral
15.
go back to reference Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T: Variable selection for propensity score models. Am J Epidemiol. 2006, 163: 1149-1156. 10.1093/aje/kwj149.CrossRefPubMedPubMedCentral Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T: Variable selection for propensity score models. Am J Epidemiol. 2006, 163: 1149-1156. 10.1093/aje/kwj149.CrossRefPubMedPubMedCentral
16.
go back to reference Senousy BE, Belal SI, Draganov PV: Hepatotoxic effects of therapies for tuberculosis. Nat Rev Gastroenterol Hepatol. 2010, 7: 543-556. 10.1038/nrgastro.2010.134.CrossRefPubMed Senousy BE, Belal SI, Draganov PV: Hepatotoxic effects of therapies for tuberculosis. Nat Rev Gastroenterol Hepatol. 2010, 7: 543-556. 10.1038/nrgastro.2010.134.CrossRefPubMed
17.
go back to reference World Health Organization Division of Traditional Medicine: General Guidelines for Methodologies on Research and Evaluation of Traditional Medicines. 2000, WHO, Geneva World Health Organization Division of Traditional Medicine: General Guidelines for Methodologies on Research and Evaluation of Traditional Medicines. 2000, WHO, Geneva
18.
go back to reference Liu Q, Garner P, Wang Y, Huang B, Smith H: Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: systematic review of ingredients and evaluation studies. BMC Public Health. 2008, 8: 365-10.1186/1471-2458-8-365.CrossRefPubMedPubMedCentral Liu Q, Garner P, Wang Y, Huang B, Smith H: Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: systematic review of ingredients and evaluation studies. BMC Public Health. 2008, 8: 365-10.1186/1471-2458-8-365.CrossRefPubMedPubMedCentral
19.
go back to reference Austin PC: An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011, 46: 399-424. 10.1080/00273171.2011.568786.CrossRefPubMedPubMedCentral Austin PC: An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011, 46: 399-424. 10.1080/00273171.2011.568786.CrossRefPubMedPubMedCentral
20.
go back to reference Baser O: Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health. 2006, 9: 377-385. 10.1111/j.1524-4733.2006.00130.x.CrossRefPubMed Baser O: Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health. 2006, 9: 377-385. 10.1111/j.1524-4733.2006.00130.x.CrossRefPubMed
21.
go back to reference D’ Agostino RB: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998, 17: 2265-2281. 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B.CrossRef D’ Agostino RB: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998, 17: 2265-2281. 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B.CrossRef
22.
go back to reference Lunceford JK, Davidian M: Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med. 2004, 23: 2937-2960. 10.1002/sim.1903.CrossRefPubMed Lunceford JK, Davidian M: Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med. 2004, 23: 2937-2960. 10.1002/sim.1903.CrossRefPubMed
23.
go back to reference Kurth T, Walker AM, Glynn RJ, Chan KA, Gaziano JM, Berger K, Robins JM: Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol. 2006, 163: 262-270.CrossRefPubMed Kurth T, Walker AM, Glynn RJ, Chan KA, Gaziano JM, Berger K, Robins JM: Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol. 2006, 163: 262-270.CrossRefPubMed
24.
go back to reference Stürmer T, Rothman KJ, Glynn RJ: Insights into different results from different causal contrasts in the presence of effect-measure modification. Pharmacoepidemiol Drug Saf. 2006, 15: 698-709. 10.1002/pds.1231.CrossRefPubMedPubMedCentral Stürmer T, Rothman KJ, Glynn RJ: Insights into different results from different causal contrasts in the presence of effect-measure modification. Pharmacoepidemiol Drug Saf. 2006, 15: 698-709. 10.1002/pds.1231.CrossRefPubMedPubMedCentral
25.
go back to reference Agal S, Baijal R, Pramanik S, Patel N, Gupte P, Kamani P, Amarapurkar D: Monitoring and management of antituberculosis drug induced hepatotoxicity. Gastroenterol Hepatol. 2005, 20: 1745-1752. 10.1111/j.1440-1746.2005.04048.x.CrossRef Agal S, Baijal R, Pramanik S, Patel N, Gupte P, Kamani P, Amarapurkar D: Monitoring and management of antituberculosis drug induced hepatotoxicity. Gastroenterol Hepatol. 2005, 20: 1745-1752. 10.1111/j.1440-1746.2005.04048.x.CrossRef
26.
go back to reference McNeill L, Allen M, Estrada C, Cook P: Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest. 2003, 123: 102-106. 10.1378/chest.123.1.102.CrossRefPubMed McNeill L, Allen M, Estrada C, Cook P: Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest. 2003, 123: 102-106. 10.1378/chest.123.1.102.CrossRefPubMed
27.
go back to reference Byrd RB, Horn BR, Solomon DA, Griggs GA: Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1000 patients. JAMA. 1979, 241: 1239-1241. 10.1001/jama.1979.03290380015017.CrossRefPubMed Byrd RB, Horn BR, Solomon DA, Griggs GA: Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1000 patients. JAMA. 1979, 241: 1239-1241. 10.1001/jama.1979.03290380015017.CrossRefPubMed
28.
go back to reference Shah BR, Laupacis A, Hux JE, Austin PC: Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol. 2005, 58: 550-559. 10.1016/j.jclinepi.2004.10.016.CrossRefPubMed Shah BR, Laupacis A, Hux JE, Austin PC: Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol. 2005, 58: 550-559. 10.1016/j.jclinepi.2004.10.016.CrossRefPubMed
Metadata
Title
Effect of scheduled monitoring of liver function during anti-Tuberculosis treatment in a retrospective cohort in China
Authors
Shanshan Wu
Yinyin Xia
Xiaozhen Lv
Yuan Zhang
Shaowen Tang
Zhirong Yang
Dehua Tu
Peiyuan Deng
Shiming Cheng
Xiaomeng Wang
Yanli Yuan
Feiying Liu
Daiyu Hu
Siyan Zhan
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2012
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-12-454

Other articles of this Issue 1/2012

BMC Public Health 1/2012 Go to the issue